Your browser doesn't support javascript.
Effectiveness and safety of Ivermectin in COVID-19 patients: A prospective study at a safety-net hospital.
Ozer, Muhammet; Goksu, Suleyman Yasin; Conception, Reena; Ulker, Esad; Balderas, Rodolfo Magallanes; Mahdi, Mohammed; Manning, Zulfiya; To, Kim; Effendi, Muhammad; Anandakrishnan, Rajashree; Whitman, Marc; Gugnani, Manish.
  • Ozer M; Department of Internal Medicine, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Goksu SY; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Conception R; Department of Pharmacology, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Ulker E; Department of Internal Medicine, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Balderas RM; Department of Internal Medicine, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Mahdi M; Department of Internal Medicine, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Manning Z; Department of Internal Medicine, Capital Health Medical Center, Trenton, New Jersey, USA.
  • To K; Department of Pharmacology, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Effendi M; Department of Pharmacology, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Anandakrishnan R; Department of Infectious Diseases, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Whitman M; Department of Infectious Diseases, Capital Health Medical Center, Trenton, New Jersey, USA.
  • Gugnani M; Department of Pulmonology and Critical Care, Capital Health Medical Center, Trenton, New Jersey, USA.
J Med Virol ; 94(4): 1473-1480, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1527445
ABSTRACT
Ivermectin has been found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. It is unknown whether this inhibition of SARS-CoV-2 replication correlates with improved clinical outcomes. To assess the effectiveness and safety of ivermectin in hospitalized patients with COVID-19. A total of 286 patients with COVID-19 were included in the study. Univariate analysis of the primary mortality outcome and comparisons between treatment groups were determined. Logistic regression and propensity score matching (PSM) was used to adjust for confounders. Patients in the ivermectin group received 2 doses of Ivermectin at 200 µg/kg in addition to usual clinical care on hospital Days 1 and 3. The ivermectin group had a significantly higher length of hospital stay than the control group; however, this significance did not maintain on multivariable logistic regression analysis. The length of intensive care unit (ICU) stay and duration of mechanical ventilation were longer in the control group. However, a mortality benefit was not seen with ivermectin treatment before and after PSM (p values = 0.07 and 0.11, respectively). ICU admission, and intubation rate were not significantly different between the groups (p = 0.49, and p = 1.0, respectively). No differences were found between groups regarding the length of hospital stay, ICU admission, intubation rate, and in-hospital mortality.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ivermectin / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27469

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Ivermectin / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27469